These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

353 related articles for article (PubMed ID: 20462431)

  • 1. Inhibition of phosphatidylcholine-specific phospholipase C downregulates HER2 overexpression on plasma membrane of breast cancer cells.
    Paris L; Cecchetti S; Spadaro F; Abalsamo L; Lugini L; Pisanu ME; Iorio E; Natali PG; Ramoni C; Podo F
    Breast Cancer Res; 2010; 12(3):R27. PubMed ID: 20462431
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of phosphatidylcholine-specific phospholipase C results in loss of mesenchymal traits in metastatic breast cancer cells.
    Abalsamo L; Spadaro F; Bozzuto G; Paris L; Cecchetti S; Lugini L; Iorio E; Molinari A; Ramoni C; Podo F
    Breast Cancer Res; 2012 Mar; 14(2):R50. PubMed ID: 22429397
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phosphatidylcholine-specific phospholipase C inhibition reduces HER2-overexpression, cell proliferation and
    Paris L; Podo F; Spadaro F; Abalsamo L; Pisanu ME; Ricci A; Cecchetti S; Altabella L; Buoncervello M; Lozneanu L; Bagnoli M; Ramoni C; Canevari S; Mezzanzanica D; Iorio E; Canese R
    Oncotarget; 2017 Aug; 8(33):55022-55038. PubMed ID: 28903399
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cells.
    Anido J; Matar P; Albanell J; Guzmán M; Rojo F; Arribas J; Averbuch S; Baselga J
    Clin Cancer Res; 2003 Apr; 9(4):1274-83. PubMed ID: 12684395
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The interplay of HER2/HER3/PI3K and EGFR/HER2/PLC-γ1 signalling in breast cancer cell migration and dissemination.
    Balz LM; Bartkowiak K; Andreas A; Pantel K; Niggemann B; Zänker KS; Brandt BH; Dittmar T
    J Pathol; 2012 Jun; 227(2):234-44. PubMed ID: 22262199
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A new model system identifies epidermal growth factor receptor-human epidermal growth factor receptor 2 (HER2) and HER2-human epidermal growth factor receptor 3 heterodimers as potent inducers of oesophageal epithelial cell invasion.
    Fichter CD; Przypadlo CM; Buck A; Herbener N; Riedel B; Schäfer L; Nakagawa H; Walch A; Reinheckel T; Werner M; Lassmann S
    J Pathol; 2017 Dec; 243(4):481-495. PubMed ID: 28940194
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy.
    Lee-Hoeflich ST; Crocker L; Yao E; Pham T; Munroe X; Hoeflich KP; Sliwkowski MX; Stern HM
    Cancer Res; 2008 Jul; 68(14):5878-87. PubMed ID: 18632642
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HER2 signaling regulates HER2 localization and membrane retention.
    Jeong J; Kim W; Kim LK; VanHouten J; Wysolmerski JJ
    PLoS One; 2017; 12(4):e0174849. PubMed ID: 28369073
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhancement of the p27Kip1-mediated antiproliferative effect of trastuzumab (Herceptin) on HER2-overexpressing tumor cells.
    Marches R; Uhr JW
    Int J Cancer; 2004 Nov; 112(3):492-501. PubMed ID: 15382077
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Polyfunctional anti-human epidermal growth factor receptor 3 (anti-HER3) antibodies induced by HER3 vaccines have multiple mechanisms of antitumor activity against therapy resistant and triple negative breast cancers.
    Osada T; Hartman ZC; Wei J; Lei G; Hobeika AC; Gwin WR; Diniz MA; Spector N; Clay TM; Chen W; Morse MA; Lyerly HK
    Breast Cancer Res; 2018 Aug; 20(1):90. PubMed ID: 30092835
    [TBL] [Abstract][Full Text] [Related]  

  • 11. β-Heregulin impairs EGF induced PLC-γ1 signalling in human breast cancer cells.
    Rommerswinkel N; Keil S; Adawy A; Hengstler JG; Niggemann B; Zänker KS; Dittmar T
    Cell Signal; 2018 Dec; 52():23-34. PubMed ID: 30165102
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phosphatidylcholine-specific phospholipase C activation in epithelial ovarian cancer cells.
    Spadaro F; Ramoni C; Mezzanzanica D; Miotti S; Alberti P; Cecchetti S; Iorio E; Dolo V; Canevari S; Podo F
    Cancer Res; 2008 Aug; 68(16):6541-9. PubMed ID: 18701477
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological blockade of fatty acid synthase (FASN) reverses acquired autoresistance to trastuzumab (Herceptin by transcriptionally inhibiting 'HER2 super-expression' occurring in high-dose trastuzumab-conditioned SKBR3/Tzb100 breast cancer cells.
    Vazquez-Martin A; Colomer R; Brunet J; Menendez JA
    Int J Oncol; 2007 Oct; 31(4):769-76. PubMed ID: 17786307
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting of the HER2/HER3 signaling axis overcomes ligand-mediated resistance to trastuzumab in HER2-positive breast cancer.
    Watanabe S; Yonesaka K; Tanizaki J; Nonagase Y; Takegawa N; Haratani K; Kawakami H; Hayashi H; Takeda M; Tsurutani J; Nakagawa K
    Cancer Med; 2019 Mar; 8(3):1258-1268. PubMed ID: 30701699
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EGFR over-expression and activation in high HER2, ER negative breast cancer cell line induces trastuzumab resistance.
    Dua R; Zhang J; Nhonthachit P; Penuel E; Petropoulos C; Parry G
    Breast Cancer Res Treat; 2010 Aug; 122(3):685-97. PubMed ID: 19859802
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination efficacy of pertuzumab and trastuzumab for trastuzumab emtansine-resistant cells exhibiting attenuated lysosomal trafficking or efflux pumps upregulation.
    Yamashita-Kashima Y; Shu S; Osada M; Fujimura T; Yoshiura S; Harada N; Yoshimura Y
    Cancer Chemother Pharmacol; 2020 Nov; 86(5):641-654. PubMed ID: 32997196
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biology of HER2 and its importance in breast cancer.
    Yarden Y
    Oncology; 2001; 61 Suppl 2():1-13. PubMed ID: 11694782
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Downregulation of HER3 by a novel antisense oligonucleotide, EZN-3920, improves the antitumor activity of EGFR and HER2 tyrosine kinase inhibitors in animal models.
    Wu Y; Zhang Y; Wang M; Li Q; Qu Z; Shi V; Kraft P; Kim S; Gao Y; Pak J; Youngster S; Horak ID; Greenberger LM
    Mol Cancer Ther; 2013 Apr; 12(4):427-37. PubMed ID: 23395887
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phosphatidylcholine-specific phospholipase C inhibition down- regulates CXCR4 expression and interferes with proliferation, invasion and glycolysis in glioma cells.
    Mercurio L; Cecchetti S; Ricci A; Pacella A; Cigliana G; Bozzuto G; Podo F; Iorio E; Carpinelli G
    PLoS One; 2017; 12(4):e0176108. PubMed ID: 28423060
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Posttranscriptional upregulation of HER3 by HER2 mRNA induces trastuzumab resistance in breast cancer.
    Li X; Xu Y; Ding Y; Li C; Zhao H; Wang J; Meng S
    Mol Cancer; 2018 Aug; 17(1):113. PubMed ID: 30068375
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.